Comes at a Cost
premature deaths in the EU annually
avoidable healthcare costs in the EU each year
in avoidable hospitalisations (for the elderly)
Source: “Investing in medication adherence improves health outcomes and health system efficiency: Adherence to medicines for diabetes, hypertension, and hyperlipidaemia”, OECD Health Working Papers, No. 105.
Although we’ve made some advances in addressing non-adherence, like developing apps to support patients with reminders or conceiving less burdensome treatments, it’s not enough.
This health issue requires us to explore other avenues that, until now, have received little attention but can make all the difference.
Behaviour can influence adherence to treatment.
Behavioural science could help shed light on how to guide patients in following their treatment better.
Each patient is unique according to their needs and limitations.
Better segmentation favours enhanced support for all types of patients.
Guidance in Personalised Care
Adherence is dynamic, requiring follow-up.
Precision medicine could raise the likelihood of better care and a more promising quality of life.
But, to make this possible, it will take more than any one person or body.
With €11.9M in funding, the BEAMER project will involve the strategic collaboration of 28 public and private European partners from academia, civil society and industry.
The final product?
Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.
Information on this website reflects project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.